Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
SRRKthis companyScholar Rock Holding Corporation	$49.21	-13.39×	20.58×	0×	-13.1×	-95.8%	0.0%	0.0%	0.0%	-154.0%	-108.5%	-6.0%	0.44×	0.58×	-55.8×	6.95×	0.0%	2	6.06	1	D+
BBIOBridgeBio Pharma, Inc.	$75.34	-20.18×	-7.27×	30.05×	-25.49×	-271.4%	94.4%	-113.3%	-145.3%	35.1%	-108.5%	-3.0%	-1.31×	-3.19×	-10.72×	2.62×	0.0%	2	-0.07	2	C
BEAMBeam Therapeutics Inc.	$26.95	-34.22×	2.21×	19.62×	-196.25×	-229.8%	84.0%	-274.6%	-57.2%	-6.5%	-27.4%	-13.1%	0.24×	0.08×	-8.77×	13.09×	0.0%	2	4.01	1	C-
DYNDyne Therapeutics, Inc.	$18.43	-5.64×	2.58×	0×	-3.74×	-61.0%	0.0%	0.0%	0.0%	-45.9%	-41.0%	-16.1%	0.02×	1.99×	-75.61×	22.25×	0.0%	2	3.6	2	C+
EWTXEdgewise Therapeutics, Inc.	$45.37	-15.23×	4.89×	0×	-15.09×	-98.7%	0.0%	0.0%	0.0%	-32.1%	-36.4%	-5.6%	0.01×	0.35×	0×	19.85×	0.0%	1	75.67	2	C
IONSIonis Pharmaceuticals, Inc.	$28.90	-33.24×	25.88×	13.41×	-52.41×	-292.2%	98.3%	-40.5%	-40.4%	-77.9%	-12.0%	-2.5%	5.35×	-7.89×	-4.22×	3.83×	0.0%	2	0.89	1	D+
Peer median	—	-20.18×	2.58×	13.41×	-25.49×	-229.8%	84.0%	-40.5%	-40.4%	-32.1%	-36.4%	-5.6%	0.02×	0.08×	-8.77×	13.09×	0.0%	2	3.6	2	—